Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GalNAc-siJag1
- Development stage
- Preclinical
- Lead developer
- Sanofi
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
GalNAc-siJag1 is a hepatocyte-targeted small interfering RNA (siRNA) modified with N-acetylgalactosamine (GalNAc) that targets Jagged1 (JAG1). Developed by Sanofi in collaboration with Columbia University, GalNAc-siJag1 is designed to selectively knock down JAG1 expression in hepatocytes, thereby inhibiting the aberrant hepatocyte-to-hepatic stellate cell (HSC) Notch signaling pathway. This targeted gene silencing aims to reduce liver fibrosis and inflammation associated with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). Preclinical studies in mouse models of MASH/NASH have demonstrated that subcutaneous administration of GalNAc-siJag1 significantly decreases liver JAG1 expression, reduces Notch target gene activation, and ameliorates or reverses established liver fibrosis.
- Other names
- GalNAc-modified Jag1 siRNAGalNAc-modified siJag1GalNAc-siRNA targeting Jag1
02
Targets
JAG1 (Jagged-1 protein)
Beyond the preview
Go deeper on GalNAc-siJag1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GalNAc-siJag1.